Entac Medical, Inc., a Memphis, Tenn.-based predictive analytics company developing noninvasive devices for the prediction and diagnosis of gastrointestinal and other medical conditions, completed its Series A2 round of financing.
The round was led by Innova, with participation from i-Select Fund and Sage Fund.
The company intends to use the funds to complete development of PrevisEA.
Led by Buddy Lyons, CEO, Entac Medical is advancing PrevisEA, is a noninvasive, self-contained, disposable device that predicts, within 12 hours after surgery, the subsequent development of postoperative ileus in two clinical trials. This provides surgeons time to make timely decisions regarding oral re-feeding of patient, nutritional support, and timing of discharge.
Entac is planning additional applications of the platform technology in gastrointestinal predictive medicine and diagnostics.